The Chemistry and Cancer Scientific Program focuses on discovery of small molecule agonists / antagonists of regulatory pathways relevant to human cancer. In a chemistry-to-biology direction, novel cytotoxic natural products and total synthetic derivatives are subjected to biochemical, genetic or molecular biological studies aimed at resolving their precise mode-of-action. Alternatively, attempts to identify small molecule agonists / antagonists of regulatory pathways relevant to cancer will be prosecuted via high throughput drug screening, medicinal chemistry, peptido-mimetics, or synthetic analogs of biologic metabolites. The long-term objective is the discovery of “first-in-class” small molecule leads for rigorous pre-clinical development.
Molecular target identification of cytotoxic natural products
Smac mimetics and other means of perturbing apoptosis with synthetic chemicals
Hypoxia and discovery of small molecules capable of modulating the hypoxic response pathway
Maintain robust and widely available high-throughput screening capabilities to interrogate biological pathways and discover “first-in-class” small molecule leads
Pre-clinical evaluation of selected leads (toxicology, PK, efficacy)
How to Get Involved
The Cancer and Development Scientific Program seeks additional physicians and scientists having both broader and deeper understanding of human cancer to further collaboration of new scientific directions for HTS assays, peptidomimetic projects and new natural product opportunities.
Program meetings every other Friday morning are attended by all investigators, postdoctoral fellows, students and scientist-level technical staff
For contact information and an overview of research conducted by each member, select from the list below:
Increase Font
Decrease Font 
Internal Links:
